Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023
Lyell Immunopharma, Inc. (LYEL)
Company Research
Source: GlobeNewswire
On track to report initial clinical and translational data from lead CAR T-cell and TIL product candidates in 2024Received Orphan Drug Designation for LYL845 for the treatment of melanomaExpect to submit IND for second generation ROR1-targeted CAR T-cell product in the first half of 2024Presented nonclinical data demonstrating the ability of Lyell’s novel genetic and epigenetic reprogramming technologies to generate potent T-cell product candidates with durable cytotoxic function at multiple scientific conferencesAdvanced manufacturing innovations to reduce cost and build scale for both CAR T-cell and TIL product candidatesCash, cash equivalents and marketable securities of $562.7 million as of December 31, 2023 supports advancing pipeline into 2027 through multiple clinical milestones SOUTH SAN FRANCISCO, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage T-cell reprogramming company advancing a diverse pipeline of cell
Show less
Read more
Impact Snapshot
Event Time:
LYEL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LYEL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LYEL alerts
High impacting Lyell Immunopharma, Inc. news events
Weekly update
A roundup of the hottest topics
LYEL
News
- Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024 [Yahoo! Finance]Yahoo! Finance
- Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024GlobeNewswire
- Lyell Immunopharma: Testing The T-Cell Thesis With 2 Upcoming Data Catalysts [Seeking Alpha]Seeking Alpha
- Outpace Bio Announces Multiple Presentations at the 2024 American Association of Cancer Research (AACR) Annual Meeting [Yahoo! Finance]Yahoo! Finance
- 2seventy bio appoints Eli Casdin and Charles Newton to its board of directors [Seeking Alpha]Seeking Alpha
LYEL
Sec Filings
- 5/6/24 - Form 424B5
- 5/6/24 - Form 10-Q
- 5/6/24 - Form 8-K
- LYEL's page on the SEC website